Amelioration of Coagulation Disorders and Inflammation by Hydrogen-Rich Solution Reduces Intestinal Ischemia/Reperfusion Injury in Rats through NF-κB/NLRP3 Pathway.
Ling Yang, Yan Guo, Xin Fan, Ye Chen, Bo Yang, Ke-Xuan Liu, Jun Zhou · Mediators of inflammation · 2020
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In rats, however, hydrogen-rich saline treatment significantly increased the 24-h survival of rats to 53.33% (8 of 15 rats) in the HRS1 group and 86.67% (13 of 15 rats) in the HRS2 group, respectively ( P < 0.05 or P < 0.01). These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in rats. However, hydrogen-rich saline treatment significantly increased the 24-h survival of rats to 53.33% (8 of 15 rats) in the HRS1 group and 86.67% (13 of 15 rats) in the HRS2 group, respectively ( P < 0.05 or P < 0.01).
What the Researchers Studied
The researchers studied rats. The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
One hundred and fifty-six rats were randomly divided into four groups ( n = 39 per group): sham-operated group (SHAM), I/R group (I/R), I/R plus hydrogen-rich saline (10 mL/kg, HRS1); and I/R plus hydrogen-rich saline (20 mL/kg, HRS2). However, hydrogen-rich saline treatment significantly increased the 24-h survival of rats to 53.33% (8 of 15 rats) in the HRS1 group and 86.67% (13 of 15 rats) in the HRS2 group, respectively ( P < 0.05 or P < 0.01). The authors concluded that in summary, the present study confirmed that intestinal I/R could cause coagulation disorders and the activation of NF- κ B and NLRP3 inflammasome in rats. However, the effect of hydrogen on coagulation dysfunction after intestinal I/R and the underlying mechanism remains unclear.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was rats. The study used a preclinical animal experiment.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.